Lemon Balm for Cognitive Function

Verdict: Weak, mixed evidence for cognitive benefit

Lemon balm (Melissa officinalis) shows only weak, inconsistent evidence for improving cognitive function in healthy adults; a handful of small, dated trials hint at acute effects on attention and calmness, but memory results are mixed and no major health authority endorses it for this use.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The grade is weak (Tier C) because the human evidence rests on just four small randomized trials, all published before 2010 with no recent replication. Two acute-dose crossover studies in healthy adults (PMID 12888775, n=20; PMID 12062586, n=20) produced genuinely mixed signals: a 1600 mg dose improved memory and calmness, yet lower doses slowed memory-task speed, and in the companion trial 600 mg sharpened attention accuracy while secondary and working memory actually declined and the highest dose reduced alertness.

The two remaining trials are in dementia, not healthy cognition. An Alzheimer's RCT (PMID 12810768, n=42) found a standardized extract improved cognition (ADAS-cog, p=0.01) and reduced agitation, and a severe-dementia aromatherapy trial (PMID 12143909, n=72) cut agitation by 35% versus 11% for placebo. These measure agitation and disease-specific outcomes and cannot be extrapolated to cognitive enhancement in healthy people.

Regulatory and clinical backing is thin. The US FDA lists balm leaf extract only as a GRAS flavoring agent, not an efficacy endorsement, while EFSA, the NHS, NIH ODS, Mayo and Harvard offer no substantive assessment for cognition. Cleveland Clinic notes cautiously that one small study improved mood and thinking but calls for more research. Given the small, aging, internally inconsistent dataset, a weak grade with a warning is appropriate.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.48
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
82%
Highly consistent evidence
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L11 AI re-checkIndependent read
0.50
L5 Clinical bodiesAuthoritative stance
0.51
L2 PubMedPrimary literature
0.60
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.479
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (Lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties
PMID: 12888775 2003 RCT (double-blind) n = 20
Finding: 1600mg dose improved memory performance and increased calmness at all postdose timepoints; lower doses slowed memory task speed.
View on PubMed
Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm)
PMID: 12062586 2002 RCT (double-blind) n = 20
Finding: 600mg gave sustained improvement in Accuracy of Attention, but Secondary and Working Memory showed time/dose-specific reductions; highest dose reduced alertness.
View on PubMed
Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial
PMID: 12810768 2003 RCT (double-blind) n = 42
Finding: Extract group had significantly better cognition than placebo (ADAS-cog F=6.93, p=0.01; CDR p<0.0001); less agitation than placebo (p=0.03).
View on PubMed
Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: a double-blind, placebo-controlled trial with Melissa
PMID: 12143909 2002 RCT (double-blind) n = 72
Finding: 35% mean reduction in agitation vs 11% placebo (p<0.0001); 60% vs 14% achieved >=30% CMAI reduction; QoL improved.
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
BALM LEAVES, EXTRACT (MELISSA OFFICINALIS L.) source↗
L5c Cleveland Clinic
Cautious
A small human study found that lemon balm improved mood and cognitive (thinking) ability. source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-cognitive-function-INT-lemon-balm-001 繁體中文版 →